I am/have/had
I am looking for
Advanced Filters
Found 1 clinical trials
A Study of Opaganib in Coronavirus Disease 2019 Pneumonia
Opaganib, a sphingosine kinase-2 (SphK2) inhibitor, has been broadly tested in Phase I/II studies. Extensive nonclinical data indicates both anti-viral and anti-inflammatory activity via selective SphK2 inhibition which may prove beneficial for treating COVID-19 infection and resulting pneumonia.
opaganib
x-rays
coronavirus infection
pneumonia
covid-19
- 0 views
- 16 Feb, 2024
- 5 locations